Navigation Links
Vaccinogen's New Anti-Cancer Vaccine Commercially Available in Europe This Year
Date:2/27/2008

FREDERICK, Md., Feb. 27 /PRNewswire/ -- Vaccinogen, Inc. announced that its new vaccine to block colon cancer from recurring will be commercially available in Europe starting June 2008.

"This makes OncoVAX(R) the world's first commercially viable vaccine for colon cancer," said Dr. Michael G. Hanna, Jr., Ph.D., Chairman & CEO of Vaccinogen. "It is the beginning of our worldwide strategy of profitable distribution. Questions of the feasibility of patient specific anti-cancer therapies have been raised and this new European initiative will obviate these issues."

Pro Vaccine AG, a leading Swiss-based pharmaceutical distributor, will begin distributing OncoVAX(R) throughout Switzerland starting with Zurich and Neuchatel by June 2008. "We are very excited about the prospects of offering OncoVAX(R) to Swiss and foreign patients," said Renato Duckeck, GM of Pro Vaccine.

Pharmacenter Hungary, a rapidly growing oncology company that commercializes a broad portfolio of oncology treatments, will begin distributing the vaccine in Hungary, Czech Republic, Slovakia, Poland, Romania, Bulgaria and Slovenia starting in the third quarter of 2008. Dr. Christian Galli, Director of Business Development of Pharmacenter Hungary noted, "We recognize the excellent opportunity OncoVAX(R) provides us and the growing population of colon cancer patients in Eastern Europe."

About OncoVAX(R)

OncoVAX(R) immunotherapy is based on a decades-long attempt by scientists to transform the body's immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.

Vaccinogen's scientists prepare a vaccine from the patient's own tumor and then administer the vaccine to the patient by three weekly injections one month after surgery. A fourth "booster" is administered six months later. OncoVAX(R) reduces recurrence and deaths by over 50%.

About Vaccinogen

Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products -- Turning Cancer on Itself(TM). Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, anti- inflammatory diseases and fully human monoclonal antibodies in various stages of clinical development. The Company maintains a European subsidiary in Emmen, The Netherlands that operates a fully functioning cGMP manufacturing center for producing OncoVAX(R) vaccines.
http://www.vaccinogeninc.com

Contact:

Andrew L. Tussing

Vaccinogen

atussing@vaccinogeninc.com

301-668-8400


'/>"/>
SOURCE Vaccinogen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
2. Egenix Licenses Harvard Anti-Cancer Platform
3. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
4. Modifying an anti-cancer drug makes it more specific
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
7. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
8. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
9. Combination vaccine protects monkeys from ebola and Marburg viruses
10. Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks
11. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... ... October 10, 2017 , ... The ... prestigious awards honoring scientists who have made outstanding contributions to analytical ... during Pittcon 2018, the world’s leading conference and exposition for laboratory science, which ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... ... a four-tiered line of medical marijuana products targeting the needs of consumers who ... packaging of Kindred takes place in Phoenix, Arizona. , As operators of two ...
(Date:10/7/2017)... 2017  The 2017 Nobel Prize in Chemistry ... Dubochet, Joachim Frank and Richard ... microscopy (cryo-EM) have helped to broaden the ... community. The winners worked with systems manufactured by ... highly resolved, three-dimensional images of protein structures that ...
Breaking Biology Technology:
(Date:8/15/2017)... ivWatch LLC , a medical device company focused on improving the ... its ISO 13485 Certification, the global standard for medical device quality ... ... device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it validates ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) is ... tech event dedicated to developing collaboration between startups and global ... June 15-17. During the event, nine startups will showcase the ... in various industries. France ... international market, with a 30 percent increase in the number ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
Breaking Biology News(10 mins):